Solar ultraviolet (sUV) irradiation is a major environmental carcinogen that can cause inflammation and skin cancer. The costs and morbidity associated with skin cancer are increasing, and therefore identifying molecules that can help prevent skin carcinogenesis is important. In this study, we identified the p53-related protein kinase (PRPK) as a novel oncogenic protein that is phosphorylated by the T-LAK cell-originated protein kinase (TOPK). Knockdown of TOPK inhibited PRPK phosphorylation and conferred resistance to solar-simulated light (SSL)-induced skin carcinogenesis in mouse models. In the clinic, acute SSL irradiation significantly increased epidermal thickness as well as total protein and phosphorylation levels of TOPK and PRPK in human skin tissues. We identified two PRPK inhibitors, FDA-approved rocuronium bromide (Zemuron ® ) or betamethasone 17-valerate (Betaderm ® ) that could attenuate TOPK-dependent PRPK signaling. Importantly, topical application of either rocuronium bromide or betamethasone decreased SSL-induced epidermal hyperplasia, neovascularization, and cutaneous squamous cell carcinoma (cSCC) development in SKH1 (Crl: SKH1-Hr hr ) hairless mice by inhibiting PRPK activation, and also reduced expression of the proliferation and oncogenesis markers, COX-2, cyclin D1, and MMP-9. This study is the first to demonstrate that targeting PRPK could be useful against sUV-induced cSCC development.
Introduction
Skin cancer has an estimated annual incidence of 700,000 cases in the United States [1] [2] [3] . In particular, the incidence of cutaneous squamous cell carcinoma (cSCC), a type of nonmelanoma skin cancer (NMSC), is increasing dramatically every year. Surgery is an effective treatment against earlystage NMSC. Nonetheless, cSCC accounts for approximately 20% of all cutaneous malignancies; and 4% of cSCC can reoccur locally or metastasize to regional lymph nodes or distant organs resulting in death, with a 5-year survival rate that is less than 20% for patients with cSCC metastases [4] [5] [6] [7] . The costs and morbidity associated with skin cancer are rising every year, and therefore effective preventive or therapeutic strategies are needed. Solar ultraviolet (sUV) irradiation is a major environmental carcinogen that causes inflammation and skin cancer. Long-term exposure of sUV irradiation to skin induces inflammatory responses, oxidative stress, DNA damage, gene mutations, and immunosuppressive responses, which altogether have been implicated in various skin diseases, including an increased risk of skin cancers. Actinic keratosis (AK), induced by sUV irradiation, acts as precursor to cSCC and is a pre-malignant skin lesion characterized with an abnormal proliferation of atypical keratinocytes confined to the epidermis of the skin [8] . Therefore, to intervene at a premalignant stage with chemopreventive strategies before development of cSCC, as well as preventing metastasis of cSCC, seems reasonable.
Metastasis of cSCC is characterized by rapid growth that is associated with increased angiogenesis, invasion, colonization, and eventually proliferation to other organs [9] . Chronic UV irradiation increases the expression of cyclooxygenase-2 (COX-2), which is the primary source to elevate the production of prostaglandin E2 (PGE2) in the skin, and this prostaglandin plays a key role in skin carcinogenesis by contributing to the uncontrolled proliferation of damaged cells that eventually form tumors [10, 11] . The important proliferation marker cyclin D1, which contributes to malignant progression in most human cancers, is overexpressed in SCC and basal cell carcinoma (BCC) [12, 13] . Another important marker for cancer progression is the matrix metalloproteinase (MMP) family of proteins, which are essential for degradation of the extracellular matrix allowing tumor cells to invade other organs. Furthermore, Notch1 is downregulated in solar keratoses and invasive SCCs arising on sUV-exposed skin suggest a tumor suppressor effect for the Notch signaling pathway in UVrelated squamous cell photocarcinogenesis [14] .
Identifying the major signaling molecules in cSCC development is therefore a critically important task. We previously reported that the T-LAK cell-originated protein kinase (TOPK) is a member of the MAPK protein family and a potential oncogene in the transformation of colorectal cancer [15] . TOPK is also highly overexpressed in many types of human cancers, including colon, lung, and breast cancers [16] [17] [18] .
Here, we identified the p53-related protein kinase (PRPK) as a novel kinase downstream of TOPK that promotes skin carcinogenesis. PRPK was originally discovered and named by Abe et al. [19] , but the authors eventually concluded that PRPK might not be directly associated with p53-dependent cell proliferation [20] . Furthermore, Peterson et al. suggested that p53 phosphorylation is not the major role of PRPK [21] .
We show that PRPK is a novel molecular driver and critical player in skin carcinogenesis, and that it is directly phosphorylated and activated by TOPK. Targeting PRPK with the FDA-approved drugs, rocuronium bromide (Zemuron ® ) or betamethasone 17-valerate (Betaderm ® ), suppressed chronic solar-simulated light (SSL)-induced cSCC development and decreased expression of COX-2, cyclin, D1 and MMP-9 in SKH1 (Crl: SKH1-Hr hr ) hairless mice. Thus, molecular targeting of PRPK could be an effective approach in the clinic to treat or prevent cSCC.
Results

Knockout of TOPK completely blocks SSL-induced skin cancer
To investigate the role of TOPK in skin carcinogenesis, we examined the status of TOPK in human skin samples. We detected high levels of total and phosphorylated TOPK (Thr9) protein expression in SCC and BCC (Fig. 1a ), and phosphorylated TOPK (Thr9) levels were also markedly higher in AKs and SCCs from patients compared to matched normal skin ( Fig. 1b ).
Next, we examined chronic SSL-induced skin carcinogenesis in TOPK knockout (TOPK −/− ) and wild-type (TOPK +/+ ) control SKH1 (Crl: SKH1-Hr hr ) hairless mice. Interestingly, TOPK −/− mice showed no tumors on SSLexposed skin tissues ( Fig. 1c, d) . In contrast, TOPK +/+ mice treated with SSL showed increased tumor volume ( Fig. 1c ) and number ( Fig. 1d ). Furthermore, TOPK −/− mice showed base levels of epidermal thickness similar to the SSLunexposed control group, but SSL-treated TOPK +/+ mice showed markedly thicker epidermal changes ( Fig. 1e ). Moreover, the Ki-67 proliferation marker was decreased in SSL-exposed TOPK −/− mouse skin compared to SKH1 TOPK +/+ mice ( Fig. 1f ). Notably, levels of the antiapoptotic protein Bcl-2 were decreased in TOPK −/− mice, compared to SSL-treated TOPK +/+ mice (Fig. 1g ). These results suggest that TOPK is important in the development of skin carcinogenesis and exerts anti-apoptotic effects in SSL-exposed mouse skin.
We also examined phosphorylated and total TOPK protein levels in human primary SCCs and SCCs metastasized to skin or lymph nodes. Our results indicated that phosphorylated and total TOPK protein levels in SCC metastasized to skin or lymph nodes were significantly higher compared to human SCC primary tumors. Results of Pearson's correlation coefficient (σ) analysis showed a positive correlation between tumor stage and tumors metastasized to skin or lymph nodes with values of 0.6405 for phosphorylated TOPK ( Supplementary Fig. 1A ) and 0.7529 for total TOPK ( Supplementary Fig. 1B ). These results indicated that phosphorylated and total TOPK proteins are associated with both SCC development and metastasis.
PRPK is a novel oncogenic kinase phosphorylated by TOPK in skin carcinogenesis
Our results so far suggest that TOPK is involved in skin carcinogenesis; however, whether TOPK or one of its downstream targets is directly involved is unclear. To identify the downstream phosphorylation targets of TOPK, we performed an in vitro kinase assay and screened several potential protein substrates. Results indicated that TOPK phosphorylated PRPK in vitro. The phosphorylation at Ser250 is known to be important for PRPK catalytic activity [22] , and in vitro kinase assay results confirmed that TOPK strongly phosphorylated PRPK at Ser250 ( Fig. 2a ). Furthermore, our results showed that PRPK could bind to the endogenous TOPK protein in SCC cell lines A431, SCC13, and human precancerous HaCaT keratinocytes ( Fig. 2b ). However, in normal human epidermal keratinocytes (NHEKs), PRPK, and the endogenous TOPK protein had only a low binding affinity (Fig. 2b) . These results indicate that PPRK is a downstream target of TOPK and that PRPK likely plays an important role in sUV-induced skin carcinogenesis.
Phosphorylated PRPK levels were absent in chronic SSL-exposed TOPK −/− mice, as compared with SKH1 TOPK +/+ mice ( Fig. 2c , Supplementary Fig. 2A ) as well as in TOPK −/− mice exposed to acute SSL irradiation (Supplementary Fig. 2B ). As previously reported, TOPK promotes cell migration through the mediation of the PI3-K and Akt pathways in lung cancer [23] . Therefore, we examined whether PI3-K, Akt, or PRPK were affected by TOPK status and also examined whether PRPK was directly affected by the PI3-K/Akt pathway. Results indicated that SSL-stimulated phosphorylation of PI3-K and Akt was not significantly different between TOPK +/+ and TOPK −/− mouse skin (Fig. 2c ). In contrast, phosphorylated PRPK levels were dramatically decreased in TOPK −/− mouse skin compared with TOPK +/+ mouse skin (Fig. 2c ). The presence of the PI3-K inhibitor, LY294002, did not affect PRPK phosphorylation in A431 cells ( Supplementary Fig.  3A) , indicating that the PI3-K pathway is not associated with PRPK phosphorylation. To determine the role of PRPK in skin carcinogenesis, we examined human skin samples, and detected highly phosphorylated PRPK expression in AKs and SCCs compared to normal skin ( Fig.  2d ). Furthermore, phosphorylated PRPK was overexpressed in SCC cell lines, including A431 and SCC12 ( Fig. 2e ). TOPK and PRPK phosphorylation in HaCaT cells was also increased by SSL irradiation in a dose-dependent and timedependent manner ( Fig. 2f , g). When TOPK expression was knocked down, SSL-induced PRPK phosphorylation also disappeared ( Fig. 2h ). Next, we investigated the role of PRPK in malignant growth of A431 cells and observed that knocking down PRPK expression (shPRPK), significantly decreased colony formation, as compared with shMocktransfected cells ( Fig. 2i ). Our results suggest that PRPK is a novel molecular driver associated with the TOPK pathway in skin carcinogenesis.
Discovery of rocuronium bromide and betamethasone 17-valerate as PRPK inhibitors for skin cancer prevention
To identify PRPK inhibitors that protect against cSCC development and move closer to clinical trials, we used computer-modeling analysis to screen drug candidates already approved by the Food and Drug Administration (FDA) for other applications. We identified two candidates, rocuronium bromide (abbreviation; rocuronium) and betamethasone 17-valerate (abbreviation; betamethasone), as potential PRPK inhibitors.
We constructed a computer model to dock each of these drugs to the PRPK protein. Rocuronium fit nicely into the ATP binding site of PRPK, with close contacts at the Val47, Val58, Ile116, and Leu169 residues ( Fig. 3a) . A hydrogen bond is formed between rocuronium and Ile116. Similarly, betamethasone also docked into the ATP binding site of PRPK with close contacts at the Val47, Val58, Ile116, Arg123, and Ile182 residues ( Fig. 3b ). Betamethasone forms hydrogen bonds with Ile116 and Arg123. The docking results suggest that each compound favorably binds to PRPK. However, based on the docking score, betamethasone (−6.0 kcal/mol) might bind more tightly than rocuronium (−3.8 kcal/mol) with PRPK.
We next examined the binding activity of rocuronium and betamethasone with wild-type or mutant PRPK proteins in which Val47, Val58, Arg123, or Ile182 was replaced with alanine. Rocuronium or betamethasone could interact with wild-type PRPK, and endogenous PRPK proteins isolated from the human A431 SCC cell line, but could not bind with any PRPK mutant protein ( Fig. 3c-f ). Thus, these results suggest that these sites are important for binding with PRPK. Notably, rocuronium or betamethasone inhibited SSL-induced phosphorylation of PRPK in JB6 P + mouse epidermal cells (Fig. 3g, h) . In vitro kinase assays using rocuronium or betamethasone (50 µM) and PRPK, indicated that PRPK activity was inhibited by 64% or 41%, respectively. We also performed a kinase assay to determine whether the PRPK inhibitors directly affected PI3-K or Akt activity and results indicated that neither rocuronium nor betamethasone affected PI3-K or Akt activity (Supplementary Fig. 3B, C) . Furthermore, neither rocuronium nor betamethasone affected TOPK kinase activity (Supplementary Fig. 3D ). Rocuronium or betamethasone did not absorb in either the UVB or UVA (280-400 nm) range and results indicated that the preventive effects of these compounds are not associated with UV absorption (i.e., a sunblock effect) in skin carcinogenesis ( Supplementary Fig. 4 ). Thus, our data showed that PI3-K and Akt are likely not involved in PRPK signaling. PRPK is a novel downstream substrate of TOPK and rocuronium or betamethasone is a specific PRPK inhibitor.
Anti-inflammatory effects induced by PRPK inhibition on SSL-induced human or mouse skin
Inflammation is known to contribute to tumor development [24] and we examined the effect of a 2-minimal erythema dose (MED) of SSL exposure in clinical human skin samples. For this study, participants were recruited from a pool of test subjects who had agreed to be re-contacted for future studies and had been previously screened and/or participated in previous skin chemoprevention trials. The eligibility criteria for participants included an age of 18 years or older and the Fitzpatrick skin type II (burns easily, tans poorly) or III (burns moderately, tans gradually). Our results indicated that acute SSL irradiation increased epidermal thickness as a feature of inflammation and also enhanced total protein and phosphorylation levels of TOPK and PRPK in human skin in a time-dependent manner ( Fig. 4a-d) .
The significance of PRPK phosphorylation induced by skin inflammation has not been reported. Our results showed that mouse skin exhibited increased epidermal thickness, and this increase was attenuated by the application of rocuronium or betamethasone in acute SSL-exposed SKH1 hairless mice ( Fig. 4e ). Furthermore, topical treatment with rocuronium or betamethasone also decreased PRPK phosphorylation in SSL-exposed SKH1 hairless mice ( Fig. 4f-h) . These results indicate that PRPK phosphorylation is an important marker in the acute SSL-induced inflammatory response. We also examined cyclobutane pyrimidine dimer (CPD) formation because UV-induced DNA damage characterized by CPD formation is known to be an important molecular initiator for UV-induced immunosuppression and carcinogenesis in skin tissues [25, 26] . Our results indicated that acute SSL increased CPD production that was reduced by PRPK inhibitors (Supplementary Fig. 5A, B ).
Potential therapeutic or preventive value of PRPK inhibitors in skin carcinogenesis
Next, to evaluate the therapeutic or preventive value of rocuronium or betamethasone against skin carcinogenesis, we used cSCC mouse models, including an early-stage prevention model ( Supplementary Fig. 6A ; Groups 1-7, Fig. 5 ), and a late-stage prevention model ( Supplementary  Fig. 6B ; Groups 8-16, Fig. 6 ), as described in Materials and Methods. Histological features of SCC include atypical keratinocytes, dermal invasion, abundant production of Fig. 3 The FDA-approved drugs, rocuronium bromide and betamethasone 17-valerate, are identified as PRPK inhibitors. Binding modes of a rocuronium bromide and b betamethasone 17-valerate with PRPK. The binding of c rocuronium bromide or d betamethasone 17valerate with PRPK was confirmed by an in vitro pull-down assay as described in Materials and Methods. A431 cell lysates were incubated with Sepharose 4B-conjugated e rocuronium bromide or f betamethasone 17-valerate and a pull-down assay was performed. Effects of g rocuronium bromide or h betamethasone 17-valerate on SSLinduced PRPK phosphorylation in JB6 P + mouse epidermal cells large keratin pearls, an increased ratio of nucleus/cytoplasm, and acantholysis [27, 28] . Hematoxylin and eosin (H&E) staining results revealed that chronic SSL exposure induced both papilloma formation and invasive cSCC (Figs.  5a, 6a ). Furthermore, large epidermal changes, dermal invasion (Figs. 5a, 6a) , and the formation of abundant large keratin pearls were observed in the SSL-exposed group (red arrows, Figs. 5a, 6a) .
Rocuronium or betamethasone application decreased tumor volume and number in chronic SSL-exposed mouse skin in both the early-stage prevention model (Fig. 5b, c ) and the late-stage prevention model ( Fig. 6b-e ), and also inhibited PRPK phosphorylation and Ki-67 expression ( Figs. 5a, 6a ). Angiogenesis is an important feature of tumor development [29] , and we observed an increased number of large blood vessels in the dermis of the SSL-treated group. Rocuronium or betamethasone clearly inhibited SSLinduced neovascularization in tumor areas (dermal blood vessels, Figs. 5a, 6a ). Next, we examined the effects of rocuronium or betamethasone on proteins associated with the malignant progression of cSCC, including COX-2, cyclin D1, and MMP-9, in chronic SSL-exposed mouse skin. Rocuronium or betamethasone suppressed SSLinduced expression of each of these proteins in SKH1 hairless mouse skin (Figs. 5d, 6f-g) .
A high-risk feature of cSCC includes immunosuppression [30] . Thus, we examined the level of immune system markers, including interferon-γ (IFN-γ), interleukin-12 (IL-12), and PGE2, and the T-cell markers, CD3 and CD4, in mouse serum and skin tissue lysates. Downregulated T-cell receptor-related signaling mediated by tumor microenvironment induces the suppression of T-cell function and antitumor immunity in the tumor-bearing host. Very few Tcells are observed in the epidermis and dermis of SSLinduced SCCs (SSL only groups in Supplementary Fig. 7A,  B ). Upon treatment with rocuronium or betamethasone, dense T-cell infiltrates in mouse skin were observed as compared to untreated controls ( Supplementary Fig. 7A, B) . We hypothesized that the PRPK inhibitors, rocuronium and betamethasone, are associated with activation of T-cell function in the dermis and epidermis of skin. SSL-induced immunosuppressive responses are associated with production of Th2-related cytokines (IL-10) and disturbance of antigen presentation to Th1 cells producing IFN-γ [31] . Therefore, SSL-induced immunosuppression could be prevented by the production of the Th1 cytokine, IFN-γ. We observed that SSL suppressed production of IFN-γ and that rocuronium or betamethasone treatment enhanced IFN-γ levels ( Supplementary Fig. 7C, D) . Thus, the PRPK inhibitors, rocuronium or betamethasone, could attenuate SSLincreased immunosuppression by upregulating IFN-γ. IL-12 is an immunoregulatory cytokine to reverse UV-induced DNA damage and immunosuppression, and also regulates the function and development of Th1 type cells by stimulating IFN-γ production [32, 33] . Furthermore, treatment with recombinant IL-12 reversed the UV-induced immunosuppression [34] . Additionally, PGE2 plays a key role as an activator of UV-induced immunosuppression through its downregulation of the levels of IL-12 [35] . Thus, the effects of PRPK inhibitors on SSL-induced changes on the immunoregulatory cytokines, IL-12 and PGE2, were investigated. PRPK inhibitors increased the production of IL-12 in mouse serum ( Supplementary Fig. 7E , F) and mouse skin ( Supplementary Fig. 7G, H) , and decreased PGE2 levels in the skin ( Supplementary Fig. 7I, J) . Importantly, PRPK inhibitors attenuated the levels of COX-2 expression and PGE2 production in SSL-exposed skin, which might play a crucial role in the upregulation of IL-12 production. Thus, the stimulation of IFN-γ and IL-12 by PRPK inhibitors could have a pivotal role in prevention of sUV-induced immunosuppression.
Mutations of the p53 gene are usually detected in cSCC [36, 37] . The p53 mutations mainly comprise C → T substitutions located on dipyrimidine sites that are specific UV targets [38] . We found mutations of the p53 gene in human cSCC ( Supplementary Table 1 ) and SSL-exposed TOPK +/+ mice (Supplementary Table 2 , used for Fig. 1c-g) . Furthermore, mutations of the p53 gene were detected in exon 7 ( Supplementary Table 3 ) and exon 8 ( Supplementary Table 4 ) in SSL-induced cSCC from both the early-stage ( Fig. 5 ) and the late-stage prevention mouse models (Fig. 6 ). One hundred Fig. 4 Effects of PRPK inhibitors on acute SSL-induced inflammation in human or mouse skin. For clinical human tissues, the minimal erythemic dose (MED) was defined as the smallest dose of energy necessary to produce confluent erythema with four distinct borders at 24 h post-exposure. MED was determined on a buttock area previously unexposed to sunlight. Each test area was subdivided into six sub-sites (each 1 cm 2 ) corresponding to the liquid light guide pattern on the solar simulator. The solar simulator was calibrated prior to each use and a series of six increasing SSL irradiation exposures were administered to each sub-site area. Following exposure, the test sites were covered until evaluations were completed. After determination of the MED for each individual, the contralateral buttock was exposed to twice the determined MED. A 6-mm skin punch biopsy sample was collected from one buttock at baseline prior to SSL exposure and additional 4 mm punch biopsies were removed at 5 min, 1, 5, and 24 h post-SSL irradiation. IHC analysis of normal human skin (BL) without SSL exposure ( Western blot analysis to detect phosphorylated PRPK (Ser250), cyclin D1, COX-2, and MMP-9 in chronic SSL-induced cutaneous papillomas and SCC. Mice were divided into groups as follows: Group 1 = no treatment (n = 6); Group 2 = cream alone (n = 10); Group 3 = 1% rocuronium bromide alone (n = 10); Group 4 = SSL alone without cream (n = 15); Group 5 = SSL with cream (n = 14); Group 6 = 0.1% rocuronium bromide with SSL (n = 15); and Group 7 = 1% rocuronium bromide with SSL (n = 15) percent of the mutations in codon 267 were C to T substitutions. We also observed a high frequency of mutations in codons 270, 277, and 284 of the p53 gene in both human and mouse cSCC ( Supplementary Tables 1-4 ). Importantly, mutations of the p53 gene were not detected in SSL-treated skin from TOPK −/− mice or from mice treated with PRPK inhibitors. Notably, these mice did not develop SCCs.
Discussion
TOPK is an active form of MEK1 [15] , and is closely associated with the development and progression of cancers, possibly acting by continuous phosphorylation of oncogenic substrates [39, 40] . However, the mechanisms of action for TOPK and its various substrates in skin carcinogenesis are still unclear. Chronic skin inflammation induced by sUV irradiation contributes to cSCC development [24] . Furthermore, metastasis often occurs in chronic inflammatory skin conditions and increased epidermal thickness is a characteristic of sUV-induced skin inflammation [41] . According to Park et al., TOPK is associated with the inflammatory signaling pathway, including endotoxin lipopolysaccharide-induced NF-κB activation and iNos gene expression [42] . Recently, the FDA-approved antibiotic, cephalosporin [43] , and the synthetic compound, ADA-07 [44] , have been shown to suppress skin carcinogenesis by blocking TOPK activity.
Our study is the first to show that PRPK phosphorylation is induced by stimulation of skin inflammation. Our clinical data with acute exposure of human skin to SSL supports the importance of the TOPK/PRPK signaling pathway in solar UV-mediated inflammatory responses. Furthermore, skin inflammation was decreased by the PRPK inhibitors, rocuronium or betamethasone. Rocuronium is a muscle relaxant used during surgery [32] and betamethasone is generally used for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses [45] [46] [47] [48] . Both are included on the List of Essential Medicines of the World Health Organization (WHO).
PRPK (also known as TP53RK) was previously reported to phosphorylate p53 on Ser15, activating its pro-apoptotic activity, which suggested that PRPK-depleted cells would have a higher survival rate. However, the p53 protein phosphorylated on Ser15 still remains even after PRPK depletion, suggesting that this is not the major role of PRPK in p53related proliferating cells. This is probably because the p53 protein is also phosphorylated by ATR and ATM on Ser15 to provide redundancy of this activity [49] . Importantly, PRPK depletion caused a large increase of apoptosis with antimitotic agents. Knockdown of PRPK increased paclitaxel-induced apoptosis, suggesting that taxane treatment could be sensitized by PRPK inhibition to treat cancers [21] . Thus, further studies with a combination of PRPK inhibitors and taxanes could provide an approach to resolve drug resistance.
The presence of p53 mutations has been associated with an increased risk of tumor progression to malignancy and the high incidence of p53 mutations increases with histologic progression from mild dysplasia to invasive carcinoma [50, 51] . We detected no p53 mutations in the SSL-treated skin from TOPK −/− mice or from SKH1 hairless mice treated with PRPK inhibitors. These mice did not develop cSCCs, suggesting that the role of the TOPK/PRPK pathway in tumorigenesis might rely mainly on mutant p53 gain-offunction properties. Our data imply that the combination of TOPK/PRPK overexpression and p53 mutation could play a pivotal role and be a prognostic factor in poor clinical outcome, and the TOPK/PRPK/mutant p53 axis might be exploited as a diagnostic or therapeutic tool. Further studies are needed to elucidate the mechanisms of the TOPK/PRPK/ mutant p53 axis to investigate whether the TOPK/PRPK pathway affects or amplifies mutant p53 oncogenic functions by stimulating gain-of-function activities of mutant p53.
In conclusion, our study indicates that PRPK is phosphorylated by TOPK, and presents a new therapeutic target against sUV-induced skin carcinogenesis. This is also the first report to demonstrate the therapeutic efficacy of FDAapproved rocuronium and betamethasone as PRPK inhibitors and could be available immediately for clinical trial evaluation for testing the effectiveness of PRPK inhibitors against cutaneous papillomas and invasive cSCC.
Materials and methods
Human skin tissues
Normal, AK, SCC, BCC, and SSL-exposed skin tissues (MED) in humans were supplied by the University of Fig. 6 Preventive efficacy of PRPK inhibitors against cutaneous papillomas and SCC in a late-stage prevention model. a At week 30, dermal blood vessels were photographed, and tissues were collected for H&E staining and IHC to detect phosphorylated PRPK (Ser250) and Ki-67. Scale bars = 100 µm. b, c Tumor volume and d, e number were measured for 30 weeks. Data represent the mean values ± S.D., and significant differences were determined by one-way ANOVA. The asterisks (**) indicate a significant (p < 0.01) difference compared to the group treated with only SSL (Group 12). f, g Western blot analysis to detect phosphorylated PRPK (Ser250), cyclin D1, COX-2, and MMP-9 in chronic SSL-induced cutaneous papillomas and SCCs. Mice were divided into groups as follows: Group 8 = no treatment (n = 5); Group 9 = cream alone (n = 10); Group 10 = 1% rocuronium bromide alone (n = 10); Group 11 = 1% betamethasone 17-valerate alone (n = 10); Group 12 = SSL with cream (n = 15); Group 13 = 0.1% rocuronium bromide with SSL (n = 15); Group 14 = 1% rocuronium bromide with SSL (n = 15); Group 15 = 0.1% betamethasone 17-valerate with SSL (n = 15); and Group 16 = 1% betamethasone 17-valerate with SSL (n = 15) Arizona Cancer Center (Tucson, AZ). The University of Arizona Institutional Review Board approved the study (the University of Arizona Human Subjects Protection Program, FWA00004218/IRB00000291) and written informed consent was obtained from all study participants. Methods were conducted in accordance with relevant regulations and guidelines from the University of Arizona Cancer Center Scientific Review Committee. For the clinical human study with acute SSL exposure, the Multiport UV Solar Simulator Model 600 (Solar Light Co., Philadelphia, PA), corroborated by using a reflectance spectrophotometer (Minolta Chroma Meter Model CR-200; Minolta Corporation, Osaka, Japan), were used to determine the MED of SSL for each individual. The SSL light source comprised 91.3% UVA and 8.7% UVB, and the emission dosages were accurately regulated to be limited to the UVA and UVB spectra.
A human skin cancer tissue array (SK801) and human primary SCCs and SCCs metastasized to skin or lymph node samples were purchased from US Biomax (Rockville, MD).
SSL irradiation system
The SSL source consisted of UVA-340 lamps that emit both UVA (94.5%) and UVB (5.5%) irradiation that was purchased from Q-Lab Corporation (Cleveland, OH). The UVA-340 lamps provide the natural sunlight that includes both UVA and UVB in the critical short wavelength region from 365 nm down to the solar cutoff of 295 nm, with a peak emission at 340 nm.
Comparison of SKH1 TOPK wild-type and knockout mice SKH1 (Crl: SKH1-Hr hr ) TOPK knockout (TOPK −/− ) hairless mice were generated as described in Supplementary Materials and Methods. These mice were managed and maintained in the animal facilities of The Hormel Institute following the University of Minnesota Animal Care and Use Committee (IACUC) guidelines. These mice were randomly grouped by age and body weight, and 20 mice per group are typically used and treated for criteria achievement of statistical significance without investigator blinding. For the chronic SSL-treated groups, SKH1 TOPK +/+ and SKH1 TOPK −/− mice aged 6 weeks at the beginning of the study were initially exposed to an SSL dose of 37 kJ/m 2 UVA and 1.8 kJ/m 2 UVB three times per a week. The UV irradiation dose was increased by 10% each week until the 6th week, at which time the UV dose reached 60 kJ/m 2 UVA and 2.9 kJ/ m 2 UVB. This dose was maintained until week 15, at which time the SSL irradiation was discontinued. Tumor growth was monitored for an additional 20 weeks. For acute SSL exposure, the dorsal skins of TOPK +/+ and TOPK −/− mice were exposed to 1 dose of SSL (149 kJ UVA/m 2 /7.2 kJ UVB/m 2 ) and at 24 h mice were euthanized and skin tissues were collected.
Chronic SSL-induced cSCC mouse models
Female SKH1 (Crl: SKH1-Hr hr ) hairless mice (5-6 weeks old) were purchased from Charles River (Burlington, MA) and mice were maintained in The Hormel Institute vivarium following the IACUC guidelines. In order to establish the criteria for achieving statistical significance, 15 mice per group were randomly grouped. We created an oil-in-water emulsion cream (patent pending) containing 0.1% or 1% (w/w) each of rocuronium bromide (rocuronium) or betamethasone 17-valerate (betamethasone), and then treated mice with the cream with or without the respective compounds three times per a week. The cream was applied to the dorsal area of the SKH1 (Crl: SKH1-Hr hr ) hairless mouse skin without investigator blinding, 1 h before SSL irradiation exposure on the same day. At week 1, the SSL dose was 37 kJ/m 2 UVA and 1.8 kJ/m 2 UVB applied three times per week and the dose of SSL irradiation was gradually increased 10% every week. At week 6, the SSL dose was 60 kJ/m 2 UVA and 2.9 kJ/m 2 UVB and this dose was maintained until week 15. We used two separate animal models, including an early-stage prevention (Groups 1-7; Supplementary Fig. 6A ) and a late-stage prevention (Group 8-16; Supplementary Fig. 6B ) model. For the early-stage prevention model, rocuronium or betamethasone cream was applied for 29 weeks and SSL irradiation was for 15 weeks. Mice for the late-stage prevention model received SSL irradiation for 15 weeks and then SSL irradiation was discontinued. At that time, mice began receiving topical application of rocuronium or betamethasone three times per a week until week 30.
Acute SSL-induced inflammation in SKH1 hairless mice
Cream only or cream containing 0.1% or 1% (w/w) of rocuronium or betamethasone was topically applied onto the dorsal area of SKH1 hairless mice. After 1 h, SSL at a dose of 149 kJ/m 2 UVA and 7.2 kJ/m 2 UVB was applied to the mouse dorsal skin. Mice were divided into groups as described in the legend of Fig. 4 . At 24 h after SSL irradiation, mouse tissues were collected and analyzed.
Computational docking and modeling
The Modeler 9.10 program (Ben Webb at UCSF; San Francisco, CA) was used to build the PRPK structure based on the crystal structure of Bud32 (PDB entry 2VWB).
Rocuronium and betamethasone were docked to PRPK using the docking program Glide 5.9 (Schrödinger LLC; New York, NY). For docking analysis, the ATP-binding site-based receptor grid was generated, and rocuronium and betamethasone were prepared by the LigPrep program with default parameters (Schrödinger). Hydrogen atoms were added consistent with a pH 7 and the docking of rocuronium or betamethasone with PRPK was achieved with default parameters in the extra precision (XP) mode. 
In vitro pull-down assay
In vitro kinase assay
An active TOPK, or Akt1 protein with the substrate for each kinase and with or without inhibitor was incubated for 30 min in a 30°C water bath. Proteins were incubated with 10 μCi [γ-32 P] ATP and isotope-unlabeled ATP in kinase buffer containing 20 mM HEPES (pH 7.4), 1 mM dithiothreitol, 10 mM MgCl 2 , and 10 mM MnCl 2 . The incorporated radioactivity was measured by autoradiography; and for the non-radioactive kinase assay, the phosphorylated substrate was detected by Western blot analysis. The in vitro PI3-K kinase assay was performed as described previously [52] with PRPK inhibitors or LY294002 (a PI3-K inhibitor).
Anchorage-independent cell growth assay
To generate knockdown PRPK cells, pLKO.1-shPRPK or pLKO.1-mock lentivirus plasmids were co-transfected with psPAX2 and pMD2.0G into HEK 293T cells using the jet-PEI poly transfection reagent (Polyplus-transfection SA; New York, NY). The human shPRPK full hairpin sequence is #1, 5′-CCGGGAGATTATATTCAGTCCACTACTCG AGTAGTGGACTGAATATAATCTCTTTTTG-3′, and #2, 5′-CCGGCATAGACTTTGGGCTGAGTTTCTCGAGAA ACTCAGCCCAAAGTCTATGTTTTTG-3′. The viral particles containing 8 µg/mL polybrene were infected into A431 cells overnight and the medium was replaced with fresh complete growth medium. After 24 h, A431 cells were selected with 2 µg/mL of puromycin. The shMock or shPRPK-transfected A431 cells were incubated for 10 days as described previously [53] . Colony formation was observed and analyzed using a LEICA DM IRB microscope (Nikon Corporation) and the ImagePro Plus software (v.6.1) program (Media Cybernetics Inc., Rockville, MD).
Immunofluorescence staining and confocal microscopy analysis
After fixation of skin tissues with 4% formaldehyde, tissues were embedded in paraffin blocks, cut and mounted on glass slides, slides were deparaffinized and hydrated, and then permeabilized in 300 µl of 0.5% Triton X-100. For immunostaining, the primary antibody was added and then the Alexa Fluor 488-labeled secondary antibody was added. The 4,6-diamidino-2-phenylindole solution was added for nuclei staining of the cells on the skin tissues. Fluorescencelabeled proteins were analyzed using the Nikon Eclipse TE2000-E Confocal microscope with EZ-C1 software (Nikon Corporation, Minato-ku, Tokyo, Japan).
Western blot analysis
Western blot analyses were performed as described in our previous study [54] .
Statistical analyses
The GraphPad prism 5.0 software (GraphPad Software; La Jolla, CA) was used for all the statistical analyses. To compare statistical significance between three or more groups, one-way ANOVA was used and Student's t-test was used to compare between two groups. Statistical pvalues (*p < 0.05 or **p < 0.01) were considered to be statistically significant between groups. To measure the degree of association between tumor stages, the Pearson's linear correlation coefficient was calculated using MATLAB (Natick, MA).
Data availability
All data generated or analyzed during this study are included in this published article (and its Supplementary Information files).
